Invalidity dossier
US 5236707
Stabilization of human interferon
Current assignee: Dallas Biotherapeutics Inc
Added 9/23/2026, 4:30:52 PM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview: US 5,236,707 — "Stabilization of Human Interferon"
Bibliographic data (per supplied text): US Patent 5,236,707; application US07/790,670; inventor William E. Stewart II; original assignee Dallas Biotherapeutics, Inc.; priority/filing date 1991-11-08; publication (grant) date 1993-08-17; status listed as "Expired – Fee Related"; anticipated expiration 2011-11-08.
Purpose. The invention addresses stabilization of human interferon—particularly alpha and omega interferon or mixtures thereof—so that interferon retains activity during storage and in topical or solution formulations. The text notes interferons have antiviral, immunomodulating and antiproliferative effects, and that topical delivery could reduce side effects associated with injection and permit patient self-administration.
Plain-language scope (from the supplied excerpt). The invention relates to preparations and methods for stabilizing human interferon. The excerpt states that human alpha and omega interferon, or mixtures thereof, can be stabilized in solutions containing amines, "more particularly, primary aliphatic amines having from between 8 to 14 carbon atoms." It further states that "lithium salts of anionic stabilizing agents such as lithium organo sulfates also stabilize interferon." A stabilized interferon may be placed in a pharmaceutically acceptable carrier for topical administration, with further stability achieved by adding additional amine-stabilizing agents. The invention is described as applicable to natural, recombinant, and chemically synthesized or modified interferon, and to crude, semi-purified or purified interferon. Dosage levels for topical preparations using crude or partially purified natural interferons are described as ranging from about 10,000 IU/gram to 1,000,000 IU/gram. The excerpt names example stabilizing agents in the background only (e.g., protease inhibitors, cationic/anionic detergents), which are described as prior approaches, not as the invention.
Not established by this excerpt: the full text of the claims; specific claim language or claim scope; working examples and quantitative stability data; the complete description and any omitted embodiments; and the exact meaning of the classification entries shown. Litigation, ownership transfers, validity, and prior-art analysis were not examined.
Source: https://patents.google.com/patent/US5236707/en (fetched 2026-09-23).
Generated 10/1/2026, 9:44:24 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 5236707. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.